Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant

Core Insights - Cabaletta Bio has appointed Steve Gavel as Chief Commercial Officer to lead global commercial strategy for its investigational therapy rese-cel, with a planned Biologics License Application submission in 2027 for myositis [1][2][3] Company Overview - Cabaletta Bio is a clinical-stage biotechnology company focused on developing curative targeted cell therapies for autoimmune diseases, utilizing its CABA™ platform to advance engineered T cell therapies [5] Leadership Experience - Steve Gavel brings extensive experience in cell therapy, having previously led the launch of CARVYKTI at Legend Biotech and held senior roles at Celgene, Takeda Pharmaceuticals, Johnson & Johnson, and Immunex [2][3] Inducement Grant - In connection with Gavel's appointment, Cabaletta granted him an inducement equity award of 275,000 stock options at an exercise price of $2.49 per share, vesting over four years [4]